

Nan Bi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1053552/publications.pdf>

Version: 2024-02-01

87
papers

1,863
citations

331670

21
h-index

302126

39
g-index

92
all docs

92
docs citations

92
times ranked

2430
citing authors

#	ARTICLE	IF	CITATIONS
1	Spatially resolved metabolomics to discover tumor-associated metabolic alterations. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 52-57.	7.1	222
2	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-“Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy. JAMA Oncology, 2021, 7, 1178.	7.1	128
3	Lung Cancer in People’s Republic of China. Journal of Thoracic Oncology, 2020, 15, 1567-1576.	1.1	114
4	Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1378-1390.	0.8	83
5	MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Molecular Cancer, 2017, 16, 50.	19.2	79
6	Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer, 2011, 117, 5423-5431.	4.1	76
7	Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 2012, 77, 89-96.	2.0	73
8	A single nucleotide polymorphism -1131T>C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Molecular Genetics and Metabolism, 2004, 83, 280-286.	1.1	60
9	Risk Factors for Brain Metastases in Locally Advanced Non-Small Cell Lung Cancer With Definitive Chest Radiation. International Journal of Radiation Oncology Biology Physics, 2014, 89, 330-337.	0.8	59
10	Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1154-1164.	0.8	45
11	Development of a Data-Independent Targeted Metabolomics Method for Relative Quantification Using Liquid Chromatography Coupled with Tandem Mass Spectrometry. Analytical Chemistry, 2017, 89, 6954-6962.	6.5	42
12	Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis. Lung Cancer, 2018, 122, 94-99.	2.0	42
13	MiR-423-5p in brain metastasis: potential role in diagnostics and molecular biology. Cell Death and Disease, 2018, 9, 936.	6.3	41
14	Molecular predictors of brain metastasis-related microRNAs in lung adenocarcinoma. PLoS Genetics, 2019, 15, e1007888.	3.5	41
15	A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy. PLoS ONE, 2014, 9, e91388.	2.5	39
16	Cyclooxygenase-2 Genetic Variants Are Associated with Survival in Unresectable Locally Advanced Non-“Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 2383-2390.	7.0	37
17	Deep Learning Improved Clinical Target Volume Contouring Quality and Efficiency for Postoperative Radiation Therapy in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 1192.	2.8	35
18	TGF- β 1 Gene Polymorphisms for Anticipating Radiation-Induced Pneumonitis in Non-“Small-Cell Lung Cancer: Different Ethnic Association. Journal of Clinical Oncology, 2010, 28, e621-e622.	1.6	31

#	ARTICLE	IF	CITATIONS
19	Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 107-114.	0.8	28
20	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 144.	2.6	28
21	Tracheobronchial Adenoid Cystic Carcinoma: 50-Year Experience at the National Cancer Center, China. <i>Annals of Thoracic Surgery</i> , 2019, 108, 873-882.	1.3	26
22	Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1635-1643.	2.5	24
23	Postoperative Radiotherapy in Pathological T2N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. <i>Oncologist</i> , 2020, 25, e701-e708.	3.7	23
24	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. <i>Radiation Oncology</i> , 2019, 14, 106.	2.7	22
25	Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution. <i>Thoracic Cancer</i> , 2015, 6, 399-406.	1.9	21
26	Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis. <i>Translational Oncology</i> , 2018, 11, 999-1006.	3.7	20
27	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. <i>Radiation Oncology</i> , 2019, 14, 48.	2.7	20
28	Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2022, 23, 95-107.	2.6	18
29	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants. <i>JAMA Network Open</i> , 2019, 2, e1918070.	5.9	17
30	Evaluation of Automatic Segmentation Model With Dosimetric Metrics for Radiotherapy of Esophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 564737.	2.8	17
31	Clinical outcomes and radiation pneumonitis after concurrent EGFR tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 814-823.	1.9	17
32	A deep learning method for producing ventilation images from 4DCT: First comparison with technegas SPECT ventilation. <i>Medical Physics</i> , 2020, 47, 1249-1257.	3.0	16
33	Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. <i>Nature Communications</i> , 2021, 12, 3785.	12.8	16
34	MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. <i>BioMed Research International</i> , 2017, 2017, 1-10.	1.9	15
35	The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients. <i>Molecular Cancer</i> , 2022, 21, 117.	19.2	15
36	Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019, 108, 1701-1709.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. <i>Acta Oncologica</i> , 2021, 60, 627-634.	1.8	13
38	Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2017, 12, 195.	2.7	12
39	Biotransformation-based metabolomics profiling method for determining and quantitating cancer-related metabolites. <i>Journal of Chromatography A</i> , 2018, 1580, 80-89.	3.7	11
40	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. <i>Journal of Cancer</i> , 2019, 10, 1985-1990.	2.5	11
41	Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas. <i>Journal of Oncology</i> , 2021, 2021, 1-15.	1.3	10
42	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. <i>Frontiers in Oncology</i> , 2020, 10, 1499.	2.8	9
43	Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial. <i>Radiation Oncology</i> , 2020, 15, 155.	2.7	9
44	Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 687231.	4.8	9
45	Transcriptome alteration spectrum in rat lung induced by radiotherapy. <i>Scientific Reports</i> , 2019, 9, 19701.	3.3	8
46	Development of a high-coverage metabolome relative quantitative method for large-scale sample analysis. <i>Analytica Chimica Acta</i> , 2020, 1109, 44-52.	5.4	8
47	Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected stage IIIA non-small cell lung cancer: A population-based study. <i>Thoracic Cancer</i> , 2021, 12, 760-767.	1.9	8
48	Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 53-60.	2.2	8
49	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. <i>BMC Cancer</i> , 2020, 20, 901.	2.6	7
50	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 2916-2923.	1.9	7
51	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. <i>BMC Cancer</i> , 2020, 20, 278.	2.6	7
52	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 244-250.	0.6	7
53	Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution. <i>Annals of Surgical Oncology</i> , 2022, 29, 4408-4416.	1.5	7
54	Managing a radiotherapy center safely and efficiently using risk-adaptive strategies during coronavirus disease pandemic: Experience from national cancer center of China. <i>Radiation Oncology</i> , 2020, 15, 243-244.	0.6	6

#	ARTICLE	IF	CITATIONS
55	CHST15 promotes the proliferation of TEAC1 cells via multiple pathways in esophageal cancer. <i>Oncology Reports</i> , 2020, 43, 75-86.	2.6	6
56	Silence of S1 RNA binding domain 1 represses cell growth and promotes apoptosis in human non-small cell lung cancer cells. <i>Translational Lung Cancer Research</i> , 2019, 8, 760-774.	2.8	5
57	A Special Report on 2019 International Planning Competition and a Comprehensive Analysis of Its Results. <i>Frontiers in Oncology</i> , 2020, 10, 571644.	2.8	5
58	MiR-323a-3p acts as a tumor suppressor by suppressing FMR1 and predicts better esophageal squamous cell carcinoma outcome. <i>Cancer Cell International</i> , 2022, 22, 140.	4.1	5
59	Treatment outcomes of patients with stage <sc>III non-small cell lung cancer</sc> and interstitial lung diseases receiving intensity-modulated radiation therapy: A single-center experience of 85 cases. <i>Thoracic Cancer</i> , 2022, , .	1.9	5
60	Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. <i>Thoracic Cancer</i> , 2019, 10, 799-806.	1.9	4
61	Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 2379-2386.	1.2	4
62	Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 7076-7086.	1.5	4
63	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. <i>Thoracic Cancer</i> , 2021, 12, 1831-1840.	1.9	4
64	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. <i>Lung Cancer</i> , 2021, 157, 116-123.	2.0	4
65	Genetic Variations in the Transforming Growth Factor- β 21 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 599719.	2.8	4
66	Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP model. <i>Radiotherapy and Oncology</i> , 2022, 167, 34-41.	0.6	4
67	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 781340.	2.8	4
68	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage <sc>III</sc> non-small cell lung cancer treated with chemoradiotherapy. <i>Thoracic Cancer</i> , 2022, 13, 296-307.	1.9	4
69	Complete remission after hypofractionated radiotherapy for a patient with inoperable adenoid cystic carcinoma of bronchus. <i>Medicine (United States)</i> , 2018, 97, e13463.	1.0	3
70	Radiation pneumonitis complicated by <i>Pneumocystis carinii</i> in patients with thoracic neoplasia: a clinical analysis of 7 cases. <i>Cancer Communications</i> , 2019, 39, 1-4.	9.2	3
71	A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases. <i>Oncologist</i> , 2019, 24, e914-e920.	3.7	3
72	Durvalumab after concurrent chemoradiotherapy in a patient with chemotherapy-resistant unresectable stage III non-small cell lung cancer: a case report. <i>Annals of Palliative Medicine</i> , 2020, 9, 2375-2380.	1.2	3

#	ARTICLE	IF	CITATIONS
73	<scp>High-grade myofibroblastic sarcoma of the pleura: A case report and literature review. Thoracic Cancer, 2020, 11, 3011-3014.	1.9	3
74	MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer. Oncotarget, 2016, 7, 22632-22638.	1.8	3
75	The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience. Frontiers in Oncology, 2021, 11, 732883.	2.8	3
76	Sparing lung tissue with virtual block method in VMAT planning for locally advanced non-small cell lung cancer. Nuclear Science and Techniques/Hewuli, 2022, 33, 1.	3.4	3
77	Complete response induced by anti-PD-1-based immunotherapy with toripalimab in a patient with locally advanced lung adenocarcinoma who failed rapidly after concurrent chemoradiotherapy: A case report. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1511-1514.	1.5	2
78	<p>Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience</p>. Cancer Management and Research, 2020, Volume 12, 11563-11571.	1.9	2
79	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210803.	1.3	2
80	Whole exome analysis reveals the genomic profiling related to chemo-resistance in Chinese population with limited-disease small cell lung cancer. Cancer Medicine, 0, , .	2.8	2
81	<p>Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study</p>. Cancer Management and Research, 2020, Volume 12, 9643-9653.	1.9	1
82	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. BMC Cancer, 2020, 20, 877.	2.6	1
83	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. Frontiers in Oncology, 2021, 11, 618776.	2.8	1
84	The Time-series Behavior of Systemic Inflammation-immune Status in Predicting Survival of Locally Advanced Non-small Cell Lung Cancer Treated with Chemoradiotherapy. Journal of the National Cancer Center, 2021, , .	7.4	1
85	Nimotuzumab combined with radiotherapy on esophageal cancer: Preliminary study of a phase II clinical trial.. Journal of Clinical Oncology, 2012, 30, e14511-e14511.	1.6	0
86	Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 810580.	2.8	0
87	Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC. Lancet Oncology, The, 2022, 23, e158.	10.7	0